Factors affecting autologous peripheral blood stem cell collection in patients with relapsed or refractory diffuse large cell lymphoma and Hodgkin lymphoma: A single institution result of 168 patients

References

• Dazzi C, Cariello A, Rosti G, Argnani M, Sebastiani L, Ferrari E, et al. Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin's Lymphoma?. Leuk Lymphoma 2000; 39: 301–310
   PubMed Web of Science ®Google Scholar
• Deliliers G L, Annaloro C, Marconi M, Soligo D, Morandi P, Luchesini C, et al. Harvesting of autologous blood stem cells after a mobilising regimen with low-dose cyclophosphamide. Leuk Lymphoma 2002; 43: 1957–1960
   PubMed Web of Science ®Google Scholar
• Kotasek D, Shepherd K M, Sage R E, Dale B M, Norman J E, Charles P, et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 1992; 9: 11–17
   PubMed Web of Science ®Google Scholar
• McQuaker I G, Haynes A P, Stainer C, Anderson S, Russell N H. Stem cell mobilization in resistant or relapsed lymphoma. Superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide. Br J Haematol 1997; 98: 228–233
   PubMed Web of Science ®Google Scholar
• Morton J, Morton A, Bird R, Hutchins C, Durrant S. Predictors for optimal mobilization and subsequent engraftment of peripheral blood progenitor cells following intermediate dose cyclophosphamide and G-CSF. Leukemia Res 1997; 21: 21–27
   PubMed Web of Science ®Google Scholar
• Pavone V, Gaudio F, Guarini A, Perrone T, Zonno A, Curci P, et al. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant 2002; 29: 285–290
   PubMed Web of Science ®Google Scholar
• Shepherd K M, Charles P, Sage R E, Dale B M, Norman J E, Kotasek D, et al. Mobilization of haemopoietic stem cells by cyclophosphamide into the peripheral blood of patients with haematological malignancies. Clin Lab Haematol 1991; 13: 25–32
   PubMedGoogle Scholar
• Watts M J, Sullivan A M, Jamieson E, Pearce R, Fielding A, Devereux S, et al. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. J Clin Oncol 1997; 15: 535–546
   PubMed Web of Science ®Google Scholar
• Magagnoli M, Sarina B, Balzarotti M. Mobilizing potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphoma. Bone Marrow Transplant 2001; 28: 923–927
   PubMed Web of Science ®Google Scholar
• Petit J, Boqué C, Cancelas J A, Sarrà J, Muñoz J, Garcia J, et al. Feasibility of ESHAP + G-CSF as peripheral blood hematopoietic progenitor cell mobilisation regimen in resistant and relapsed lymphoma: a single-center study of 22 patients. Leuk Lymphoma 1999; 34: 119–127
   PubMed Web of Science ®Google Scholar
• Watts M J, Ings S J, Leverett D. ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m(−2) and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients. Br J Cancer 2000; 82: 278–282
   PubMed Web of Science ®Google Scholar
• Zinzani P L, Tani M, Molinari A L, Stefoni V, Zuffa E, Alinari L, et al. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. Haematologica 2002; 87: 816–821
   PubMed Web of Science ®Google Scholar
• Lee J L, Kim S, Kim S WKE, Kim S B, Kang Y K, Lee J, et al. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF. Bone Marrow Transplantation 2005; 35: 449–454
   PubMed Web of Science ®Google Scholar
• Velasquez W S, McLaughlin P, Tucker S, Hagemeister F B, Swan F, Rodriguez M A, et al. E-SHAP an effective chemotherapy in refractory and relapsing lymphoma: a 4-year follow-up. J Clin Oncol 1994; 6: 1169–1176
   Google Scholar
• Akhtar S, Tbakhi A, Humaidan H, El Weshi A, Rahal M, Maghfoor I. ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients. Bone Marrow Transplantation 2006; 37: 277–282
   PubMed Web of Science ®Google Scholar
• Brocklebank A M, Sparrow R L. Enumeration of CD341 Cells in Cord Blood: a variation on a single-platform flow cytometric method based on the ISHAGE gating strategy. Cytometry (Comm Clin Cytometry) 2001; 46: 254–261
   PubMed Web of Science ®Google Scholar
• Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K, et al. Factors that influence collection and engraftment of autologous peripheral blood stem cells. J Clin Oncol 1995; 13: 2547–2555
   PubMed Web of Science ®Google Scholar
• Clark R E, Brammer C G. Previous treatment predicts the efficiency of blood progenitor cell mobilization: validation of a chemotherapy scoring system. Bone Marrow Transplant 1998; 22: 859–863
   PubMed Web of Science ®Google Scholar
• Drake M, Ranaghan L, Morris T C, Nolan L, Desai Z R, Irvine A E, et al. Analysis of the effect of prior therapy on progenitor cell yield: use of a chemotherapy scoring system. Br J Haematol 1997; 98: 745–749
   PubMed Web of Science ®Google Scholar
• Ford C D, Chan K, Reilly W F, Petersen F B. An evaluation of predictive factors for CD34+ cell harvest yields from patients mobilized with chemotherapy and growth factors. Transfusion 2003; 43: 622–625
   PubMed Web of Science ®Google Scholar
• Micallef I N, Apostolidis J, Rohatiner A Z, Wiggins C, Crawley C R, Foran J M, et al. Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. Hematol J 2000; 1: 367–373
   PubMedGoogle Scholar
• Kuittinen T, Nousiainen T, Halonen P, Mahlamäki E, Jantunen E. Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 907–912
   PubMed Web of Science ®Google Scholar
• Ford C D, Green W, Warenski S, Petersen F B. Effect of prior chemotherapy on hematopoietic stem cell mobilization. Bone Marrow Transplant 2004; 33: 901–905
   PubMed Web of Science ®Google Scholar
• Koumakis G, Vassilomanolakis M, Hatzichristou H, Barbounis V, Filis J, Papanastasiou K, et al. Predictive factors affecting mobilization and peripheral blood stem cell (PBSC) collection using single apheresis (SA) for rescuing patients after high-dose chemotherapy (HD, CHE) in various malignancies. Bone Marrow Transplant 1996; 18: 1065–1072
   PubMed Web of Science ®Google Scholar
• Canales M A, Fernandez-Jimenez M C, Martin A, Arrieta R, Caballero M D, Diez J, et al. Identification of factors associated with poor peripheral blood progenitor cell mobilization in Hodgkin's disease. Haematologica 2001; 86: 494–498
   PubMed Web of Science ®Google Scholar
• Lee J L, Kim S B, Lee G W, Ryu M H, Kim E K, Kim S, et al. Collection of peripheral blood progenitor cells: analysis of factors predicting the yields. Transfus Apheresis Sci 2003; 29: 29–37
   PubMed Web of Science ®Google Scholar
• Ketterer N, Salles G, Moullet I, Dumontet C, ElJaafari-Corbin A, Tremisi P, et al. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 1998; 103: 235–242
   PubMed Web of Science ®Google Scholar
• Morton J A, Baker D P, Hutchins C J, Durrant S T. The COBE Spectra cell separator is more effective than the Haemonetics MCS-3P cell separator for peripheral blood progenitor cell harvest after mobilization with cyclophosphamide and filgrastim. Transfusion 1997; 37: 631–633
   PubMed Web of Science ®Google Scholar
• Jeanne M, Bouzgarrou R, Lafarge X, Fizet D, Dazey B, Vezon G, et al. Comparison of CD34+ cell collection on the CS-3000+ and Amicus blood cell separators. Transfusion 2003; 43: 1423–1427
   PubMed Web of Science ®Google Scholar
• Kessinger A, Sharp J G. The whys and hows of hematopoietic progenitor and stem cell mobilization. Bone Marrow Transplant 2003; 31: 319–329
   PubMed Web of Science ®Google Scholar